Your browser doesn't support javascript.
loading
A functional variant that affects exon-skipping and protein expression of SP140 as genetic mechanism predisposing to multiple sclerosis.
Matesanz, Fuencisla; Potenciano, Victor; Fedetz, Maria; Ramos-Mozo, Priscila; Abad-Grau, María del Mar; Karaky, Mohamad; Barrionuevo, Cristina; Izquierdo, Guillermo; Ruiz-Peña, Juan Luis; García-Sánchez, María Isabel; Lucas, Miguel; Fernández, Óscar; Leyva, Laura; Otaegui, David; Muñoz-Culla, Maider; Olascoaga, Javier; Vandenbroeck, Koen; Alloza, Iraide; Astobiza, Ianire; Antigüedad, Alfredo; Villar, Luisa María; Álvarez-Cermeño, José Carlos; Malhotra, Sunny; Comabella, Manuel; Montalban, Xavier; Saiz, Albert; Blanco, Yolanda; Arroyo, Rafael; Varadé, Jezabel; Urcelay, Elena; Alcina, Antonio.
Afiliación
  • Matesanz F; Department of Cell Biology and Immunology, Instituto de Parasitología y Biomedicina López Neyra (IPBLN), CSIC, Granada, Spain, lindo@ipb.csic.es pulgoso@ipb.csic.es.
  • Potenciano V; Department of Cell Biology and Immunology, Instituto de Parasitología y Biomedicina López Neyra (IPBLN), CSIC, Granada, Spain, Department of Computer Languages and Systems-CITIC, Universidad de Granada, Granada, Spain.
  • Fedetz M; Department of Cell Biology and Immunology, Instituto de Parasitología y Biomedicina López Neyra (IPBLN), CSIC, Granada, Spain.
  • Ramos-Mozo P; Department of Immunology and.
  • Abad-Grau Mdel M; Department of Computer Languages and Systems-CITIC, Universidad de Granada, Granada, Spain.
  • Karaky M; Department of Cell Biology and Immunology, Instituto de Parasitología y Biomedicina López Neyra (IPBLN), CSIC, Granada, Spain.
  • Barrionuevo C; Department of Cell Biology and Immunology, Instituto de Parasitología y Biomedicina López Neyra (IPBLN), CSIC, Granada, Spain.
  • Izquierdo G; Unidad de Esclerosis Múltiple, Hospital Universitario Virgen Macarena, Sevilla, Spain.
  • Ruiz-Peña JL; Unidad de Esclerosis Múltiple, Hospital Universitario Virgen Macarena, Sevilla, Spain.
  • García-Sánchez MI; Unidad de Esclerosis Múltiple, Hospital Universitario Virgen Macarena, Sevilla, Spain.
  • Lucas M; Servicio de Biología Molecular, Facultad de Medicina, Hospital Virgen Macarena, Sevilla, Spain.
  • Fernández Ó; Unidad de Gestión Clínica de Neurociencias, Instituto de Biomedicina de Málaga (IBIMA), Hospital Regional Universitario de Málaga, Málaga, Spain.
  • Leyva L; Unidad de Gestión Clínica de Neurociencias, Instituto de Biomedicina de Málaga (IBIMA), Hospital Regional Universitario de Málaga, Málaga, Spain.
  • Otaegui D; Área de Neurociencias, Inst. Investigación Sanitaria Biodonostia, San Sebastián, Spain.
  • Muñoz-Culla M; Área de Neurociencias, Inst. Investigación Sanitaria Biodonostia, San Sebastián, Spain.
  • Olascoaga J; Área de Neurociencias, Inst. Investigación Sanitaria Biodonostia, San Sebastián, Spain.
  • Vandenbroeck K; Neurogenomiks Group, Universidad del País Vasco (UPV/EHU), Leioa, Spain, Achucarro Basque Center for Neuroscience, Zamudio, Spain, IKERBASQUE, Basque Foundation for Science, Bilbao, Spain.
  • Alloza I; Neurogenomiks Group, Universidad del País Vasco (UPV/EHU), Leioa, Spain, Achucarro Basque Center for Neuroscience, Zamudio, Spain, IKERBASQUE, Basque Foundation for Science, Bilbao, Spain.
  • Astobiza I; Neurogenomiks Group, Universidad del País Vasco (UPV/EHU), Leioa, Spain, Achucarro Basque Center for Neuroscience, Zamudio, Spain.
  • Antigüedad A; Servicio de Neurología, Hospital de Basurto, Bilbao, Spain.
  • Villar LM; Department of Immunology, Department of Neurology. MS Unit. (IRYCIS), Hospital Ramon y Cajal, Madrid, Spain.
  • Álvarez-Cermeño JC; Department of Immunology, Department of Neurology. MS Unit. (IRYCIS), Hospital Ramon y Cajal, Madrid, Spain.
  • Malhotra S; Servei de Neurologia-Neuroimmunologia, Centre D'Esclerosi Múltiple de Catalunya, Cemcat, Hospital Universitari Vall d'Hebron, Barcelona, Spain and.
  • Comabella M; Servei de Neurologia-Neuroimmunologia, Centre D'Esclerosi Múltiple de Catalunya, Cemcat, Hospital Universitari Vall d'Hebron, Barcelona, Spain and.
  • Montalban X; Servei de Neurologia-Neuroimmunologia, Centre D'Esclerosi Múltiple de Catalunya, Cemcat, Hospital Universitari Vall d'Hebron, Barcelona, Spain and.
  • Saiz A; Neurology Service, Hospital Clinic and I. d'Investigació Biomèdica Pi iSunyer (IDIBAPS), Barcelona, Spain.
  • Blanco Y; Neurology Service, Hospital Clinic and I. d'Investigació Biomèdica Pi iSunyer (IDIBAPS), Barcelona, Spain.
  • Arroyo R; Multiple Sclerosis Unit, Hospital Clínico San Carlos. Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.
  • Varadé J; Department of Immunology and.
  • Urcelay E; Department of Immunology and.
  • Alcina A; Department of Cell Biology and Immunology, Instituto de Parasitología y Biomedicina López Neyra (IPBLN), CSIC, Granada, Spain, lindo@ipb.csic.es pulgoso@ipb.csic.es.
Hum Mol Genet ; 24(19): 5619-27, 2015 Oct 01.
Article en En | MEDLINE | ID: mdl-26152201
ABSTRACT
Several variants in strong linkage disequilibrium (LD) at the SP140 locus have been associated with multiple sclerosis (MS), Crohn's disease (CD) and chronic lymphocytic leukemia (CLL). To determine the causal polymorphism, we have integrated high-density data sets of expression quantitative trait loci (eQTL), using GEUVADIS RNA sequences and 1000 Genomes genotypes, with MS-risk variants of the high-density Immunochip array performed by the International Multiple Sclerosis Genetic Consortium (IMSGC). The variants most associated with MS were also correlated with a decreased expression of the full-length RNA isoform of SP140 and an increase of an isoform lacking exon 7. By exon splicing assay, we have demonstrated that the rs28445040 variant was the causal factor for skipping of exon 7. Western blots of peripheral blood mononuclear cells from MS patients showed a significant allele-dependent reduction of the SP140 protein expression. To confirm the association of this functional variant with MS and to compare it with the best-associated variant previously reported by GWAS (rs10201872), a case-control study including 4384 MS patients and 3197 controls was performed. Both variants, in strong LD (r(2) = 0.93), were found similarly associated with MS [P-values, odds ratios 1.9E-9, OR = 1.35 (1.22-1.49) and 4.9E-10, OR = 1.37 (1.24-1.51), respectively]. In conclusion, our data uncover the causal variant for the SP140 locus and the molecular mechanism associated with MS risk. In addition, this study and others previously reported strongly suggest that this functional variant may be shared with other immune-mediated diseases as CD and CLL.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Factores de Transcripción / Polimorfismo de Nucleótido Simple / Antígenos Nucleares / Esclerosis Múltiple Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Hum Mol Genet Asunto de la revista: BIOLOGIA MOLECULAR / GENETICA MEDICA Año: 2015 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Factores de Transcripción / Polimorfismo de Nucleótido Simple / Antígenos Nucleares / Esclerosis Múltiple Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Hum Mol Genet Asunto de la revista: BIOLOGIA MOLECULAR / GENETICA MEDICA Año: 2015 Tipo del documento: Article